Walleye Capital
CERE

Walleye Capital’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Walleye Capital’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,900
Closed -$95.1K – 5008
2023
Q1 		$95.1K Sell
3,900
-2,500
-39% -$73.4K ﹤0.01% 2960
2022
Q4 		$202K Buy
+6,400
New +$181K ﹤0.01% 2042

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Walleye Capital's CERE Position: Q3 2024 in Review

Walleye Capital sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 40,000 shares — an estimated $1.64M sold.

Walleye Capital first reported a position in CERE in Q4 2023 and held it in 3 quarters. The position peaked at $1.69M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Walleye Capital reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Walleye Capital sold 40,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $1.64M.
  • Walleye Capital first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 3 quarters.
  • Walleye Capital's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.69M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Walleye Capital's 13F filing for Q3 2024, filed 14 Nov 2024.